New scan spots prostate cancer that standard tests miss

NCT ID NCT04655365

Ongoing Diagnosis Sponsor: CHU de Quebec-Universite Laval Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a special PET scan (18F-DCFPyL) to see if it can find prostate cancer spread that standard scans miss. Fifty men with castration-resistant prostate cancer starting enzalutamide will get the new scan. The goal is to better detect and monitor metastases, which could help guide treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-DCFPyL (a radioactive tracer for PET scans) and enzalutamide (a hormone therapy drug)
What this could lead to: If successful, this could improve how doctors detect and monitor prostate cancer spread, leading to more personalized treatment decisions.
What could go wrong: This is a small, early-phase study focused on imaging accuracy, not on treatment outcomes. The new scan may not change patient survival or quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

CHU de Québec-Université Laval

Québec, Quebec, Canada
CHUM

Montreal, Quebec, H2X 0A9, Canada
CIUSSS de l'Estrie - CHUS

Sherbrooke, Quebec, J1J 3H5, Canada
CUSM

Montreal, Quebec, H3H 2R9,, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.